Product Description
For Acute Ischemic Stroke (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00827190)
Mechanisms of Action: L-Type Calcium Channel Binder
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Ischemic Stroke
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00827190 |
3216K1-1000 | P1 |
Completed |
Ischemic Stroke |
2009-07-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|